

Neuroprotection

Part II: Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 175 articles out of a total of 1250 articles by 450 authors. These articles are updated on a yearly basis. Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2020) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

Prof. Jain has been involved in various neuroprotective strategies during his active neurosurgical career including use of hypothermia, hyperbaric oxygen and induced coma. He has a personal experience of methods of neuroprotection used in the care of patients with stroke and CNS trauma as well as during neurosurgical operations.

November 2021 (first edition in April 2000)
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

14. Markets for Neuroprotective Therapies.....	5
Introduction	5
The financial burden of CNS damage	5
Markets for neuroprotective therapies.....	5
Markets according to therapeutic areas.....	5
<i>Stroke</i>	<i>6</i>
<i>CNS injury</i>	<i>6</i>
<i>Alzheimer disease</i>	<i>6</i>
<i>Parkinson disease</i>	<i>7</i>
<i>Multiple sclerosis.....</i>	<i>7</i>
<i>Epilepsy.....</i>	<i>7</i>
Values of neuroprotective therapies in major world markets.....	7
Unmet needs in neuroprotectives.....	8
Future of neuroprotective therapies	10
Challenges in neuroprotective drug development	10
Promising areas of research in neuroprotection.....	10
<i>Autoreactive antibodies</i>	<i>11</i>
<i>Biological therapies for neuroprotection</i>	<i>11</i>
<i>Multidisciplinary approaches to neuroprotection</i>	<i>11</i>
15. Companies Developing Neuroprotective Therapies	13
Introduction	13
Profiles of companies.....	13
Collaborations.....	165
16. References.....	169

Tables

Table 14-1: Neuroprotective market values 2020-2030	6
Table 14-2: Values of neuroprotective therapies in major world markets from 2020-30	7
Table 15-1: Pipeline of Alkahest	23
Table 15-2: Collaborations of companies in the area of neuroprotection.....	165

Figures

Figure 14-1: Unmet therapeutic needs in neuroprotective therapies	9
Figure 15-1: Neurovive's pipeline.....	106